Opioid receptor modulators and use thereof
Disclosed is an in vitro screening method for identifying an antagonist-to-agonist allosteric modifier of a mu-opioid receptor and an in vivo method for confirming that a test compound is such a modifier of a mu-opioid receptor. Also disclosed is a method for treating an opioid receptor-associated condition using a compound of Formula (I) and a pharmaceutical composition containing the same.
1. A pharmaceutical composition for treating an opioid receptor-associated condition, the pharmaceutical composition comprising a pharmaceutically acceptable carrier, a mu-opioid receptor antagonist, and a compound of Formula (I):
wherein
U is H, C 1-6 alkyl, C 3-8 cycloalkyl, C 2-8 heterocycloalkyl, C 6-14 aryl, or C 1-13 heteroaryl;
V is H, C 1-6 alkyl, C 3-8 cycloalkyl, C 2-8 heterocycloalkyl, or C 1-13 heteroaryl; and
Z is O or S,
in which
each of C 1-6 alkyl, C 3-8 cycloalkyl, C 2-8 heterocycloalkyl, C 6-14 aryl, and C 1-13 heteroaryl, independently, is optionally mono-, di-, or tri-substituted with halo, OH, CN, NH 2 , NO 2 , COOH, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 3-8 cycloalkyl, C 2-8 heterocycloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, C 1-6 alkylamino, C 2-6 dialkylamino, C 7-12 aralkyl, C 1-12 heteroaralkyl, —C(O)OR, —C(O)NRR′, —NRC(O)R′, —S(O) 2 R, —S(O) 2 NRR′, —NRS(O) 2 R′, —C(O)R, or —NRS(O) 2 NR′R″; or is optionally fused with C 3-8 cycloalkyl, C 2-8 heterocycloalkyl, C 6-14 aryl, or C 1-13 heteroaryl; each of R, R′, and R″, independently, being H, halo, OH, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 3-8 cycloalkyl, C 2-8 heterocycloalkyl, C 6-14 aryl, or C 1-13 heteroaryl.
2. The pharmaceutical composition of claim 1 , wherein U is
3. The pharmaceutical composition of claim 2 , wherein V is
4. The pharmaceutical composition of claim 1 , wherein V is
5. The pharmaceutical composition of claim 1 , wherein the compound is one of Compounds 1, 4, 6, 8, 10, 12, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41-43, 45, 47, 49, 51, 53, 55, 57, 62, 65, 68, 70, 72, 75, 82, 85, 87, 89, 92, 93-95, 98, 102, 105-107, 109, 111, 114, 117, 126, 128, 129, 131, and 132.
6. The pharmaceutical composition of claim 5 , wherein the opioid receptor-associated condition is pain, and the mu-opioid receptor antagonist is naloxone, naltrexone, or samidorphan.
7. The pharmaceutical composition of claim 6 , wherein the compound is one of Compounds 1, 17, 29, 33, 47, 85, 95, 102, and 106.
8. The pharmaceutical composition of claim 7 , wherein the compound is Compound 1.
9. The pharmaceutical composition of claim 1 , wherein the mu-opioid receptor antagonist is naloxone, naltrexone, or samidorphan.
10. The pharmaceutical composition of claim 1 , wherein the opioid receptor-associated condition is pain, immune disease, esophageal reflux, diarrhea, anxiety, heroin addiction, or cough.
11. The pharmaceutical composition of claim 10 , wherein the opioid receptor-associated condition is pain.
12. A method of treating an opioid receptor-associated condition, the method comprising administering to a subject in need thereof a pharmaceutical composition of claim 8 , wherein the pharmaceutical composition contains a mu-opioid receptor antagonist and an effective amount of a compound of Formula (I):
wherein
U is H, C 1-6 alkyl, C 3-8 cycloalkyl, C 2-8 heterocycloalkyl, C 6-14 aryl, or C 1-13 heteroaryl;
V is H, C 1-6 alkyl, C 3-8 cycloalkyl, C 2-8 heterocycloalkyl, or C 1-13 heteroaryl; and
Z is O or S,
in which
each of C 1-6 alkyl, C 3-8 cycloalkyl, C 2-8 heterocycloalkyl, C 6-14 aryl, and C 1-13 heteroaryl, independently, is optionally mono-, di-, or tri-substituted with halo, OH, CN, NH 2 , NO 2 , COOH, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 3-8 cycloalkyl, C 2-8 heterocycloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, C 1-6 alkylamino, C 2-6 dialkylamino, C 7-12 aralkyl, C 1-12 heteroaralkyl, —C(O)OR, —C(O)NRR′, —NRC(O)R′, —S(O) 2 R, —S(O) 2 NRR′, —NRS(O) 2 R′, —C(O)R, or —NRS(O) 2 NR′R″; or is optionally fused with C 3-8 cycloalkyl, C 2-8 heterocycloalkyl, C 6-14 aryl, or C 1-13 heteroaryl; each of R, R′, and R″, independently, being H, halo, OH, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 3-8 cycloalkyl, C 2-8 heterocycloalkyl, C 6-14 aryl, or C 1-13 heteroaryl,
or a pharmaceutically acceptable salt of the compound.
13. The method of claim 12 , wherein the mu-opioid receptor antagonist is naloxone, naltrexone, or samidorphan.
14. The method of claim 12 , wherein the opioid receptor-associated condition is pain, immune disease, esophageal reflux, diarrhea, anxiety, heroin addiction, or cough.
15. The method of claim 14 , wherein the opioid receptor-associated condition is pain.
16. The method of claim 15 , wherein the compound is Compound 1, 17, 29, 33, 47, 85, 95, 102, or 106.
17. The method of claim 16 , wherein the compound is Compound 1.
18. The method of claim 15 , wherein the pain is renal colic, acute pancreatitis, angina, chronic neuropathic pain, chronic regional complex pain syndrome, or cancer pain.